8-K/A: Recursion Pharmaceuticals Completes Acquisition of Exscientia, Pro Forma Financials Released

Recursion Pharmaceuticals has finalized its acquisition of Exscientia, with pro forma financial statements now available reflecting the combined entity.

Summary

• Recursion Pharmaceuticals acquired Exscientia on November 19, 2024, making Exscientia a wholly-owned subsidiary.
• The acquisition was completed through a share exchange, with Exscientia shareholders receiving 0.7729 shares of Recursion stock for each Exscientia share.
• The total estimated purchase price is approximately $635.9 million, including the value of shares and replacement equity awards.
• Pro forma financial statements combine the historical results of both companies as if the transaction occurred on January 1, 2023, for the income statement and September 30, 2024, for the balance sheet.
• The pro forma statements include adjustments to reconcile Exscientia's IFRS financials to U.S. GAAP and to account for the acquisition.

Sentiment

Score: 4

Explanation: The document details a completed acquisition, which is positive, but the significant pro forma losses and preliminary nature of the financials temper the overall sentiment. The high purchase price and integration risks also contribute to a lower score.

Positives

• The acquisition of Exscientia expands Recursion's capabilities and market presence.
• The pro forma financials provide a clear picture of the combined entity's financial position.
• The transaction has been completed, removing uncertainty about the acquisition.

Negatives

• The combined company has significant net losses, with a pro forma net loss of $548.7 million for 2023 and $476.5 million for the first nine months of 2024.
• The pro forma financial information is preliminary and subject to further revision.
• The combined company's future performance is uncertain and may not reflect the pro forma results.

Risks

• The pro forma financial information may not accurately reflect the future financial performance of the combined company.
• The integration of Exscientia's operations and accounting policies may present challenges.
• The combined company may not achieve the anticipated synergies or cost savings from the acquisition.
• The final purchase price allocation is subject to change and may materially impact the financial statements.

Future Outlook

The pro forma financial information is not necessarily indicative of future results or the financial position of the combined company, and does not reflect any anticipated synergies or cost savings.

Industry Context

The acquisition reflects a trend of consolidation in the biotechnology and pharmaceutical industries, where companies seek to expand their capabilities and pipelines through strategic mergers and acquisitions.

Comparison to Industry Standards

• The acquisition of Exscientia by Recursion is a significant transaction in the AI-driven drug discovery space, similar to other mergers and acquisitions in the biotech sector.
• Comparable companies in the AI-driven drug discovery space include Schrodinger and Relay Therapeutics, which have also pursued strategic partnerships and acquisitions to enhance their platforms.
• The pro forma net losses are substantial, which is not uncommon for companies in the early stages of drug development, but the combined entity will need to demonstrate progress towards profitability.
• The purchase price of $635.9 million is a significant investment, and the success of the acquisition will depend on the combined company's ability to integrate operations and realize synergies.

Stakeholder Impact

• Shareholders of Exscientia received Recursion shares, impacting their ownership and investment.
• Recursion shareholders now own a stake in a larger, combined entity.
• Employees of both companies may experience changes in their roles and responsibilities.
• Customers and partners of both companies may see changes in the products and services offered.

Next Steps

• Recursion will continue to refine its identification and valuation of assets to be acquired and liabilities to be assumed.
• Recursion management will continue to perform a detailed review of Exscientia's accounting policies.
• The final determination of the purchase price allocation will be completed as soon as practicable but not one year beyond the date of the closing date of the Transaction.

Key Dates

Keywords

Acquisition, Recursion Pharmaceuticals, Exscientia, Pro Forma Financials, Merger, Business Combination, Share Exchange, Biotechnology, Pharmaceuticals